Pramipexole
Pronunciation: pronunciation varies by local usage.
- Generic name
- pramipexole
- Brand names
- Mirapex
- Drug class
- Dopamine agonist
- Form
- Tablets
- Route
- Oral
- Legal status
- Prescription-only medicine
Availability and supply rules vary by country
Trade names by country: Canada
Australia: · Full directory
What pramipexole is and how it works
Pramipexole is a dopamine agonist indicated for the signs and symptoms of idiopathic Parkinson's disease and for moderate-to-severe primary Restless Legs Syndrome (RLS). (1)
It is used under specialist supervision; dosing and titration must be individualized. It is not for all types of parkinsonism or restless legs.
Mechanism of action: how pramipexole works
Pramipexole is a non-ergot dopamine agonist. Its exact mechanism in Parkinson's disease and RLS is not fully established. (1)
What pramipexole is used for
Parkinson's disease
Treatment of the signs and symptoms of idiopathic Parkinson's disease. (1)
Restless Legs Syndrome (RLS)
Treatment of moderate-to-severe primary Restless Legs Syndrome. (1)
Before taking pramipexole
Do not take / not appropriate for
- Do not take pramipexole if you have had a hypersensitivity reaction to pramipexole or any of its ingredients. (all products) (1)
Tell your clinician about
- Any episodes of falling asleep during daily activities, including driving, or if you experience sudden onset of sleep without warning.
- Dizziness, lightheadedness, or fainting, especially when standing up from sitting or lying.
- New or increased urges to gamble, compulsive sexual behavior, binge eating, or uncontrolled shopping.
- Hallucinations (seeing, hearing, or feeling things that are not there).
- Worsening of involuntary movements (dyskinesia) if taking levodopa.
- If you plan to become pregnant, are pregnant, or are breastfeeding.
- All medicines you take, especially cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine, or dopamine-blocking drugs (neuroleptics, metoclopramide).
How to take pramipexole
- Take pramipexole exactly as prescribed. For Parkinson's disease, the starting dose is usually 0.375 mg per day in three divided doses, increased gradually every 5–7 days by the prescriber. For RLS, start with 0.125 mg once daily, taken 2–3 hours before bedtime, increased every 4–7 days as directed.
- Rise slowly from sitting or lying to minimize dizziness.
- Do not change the dose, number of tablets, or stop taking pramipexole without consulting the prescriber.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1)
Missed dose
No specific missed-dose guidance was provided in the research notes. Always follow the prescriber's instructions.
Overdose
No specific overdose information is provided in the research notes. In case of suspected overdose, contact emergency services or a poison control center immediately. Do not attempt to treat yourself.
Side effects
Side effects vary by indication. The most common adverse reactions in early Parkinson's disease are nausea, dizziness, somnolence, insomnia, constipation, asthenia, and hallucinations. In advanced Parkinson's disease, postural hypotension, dyskinesia, extrapyramidal syndrome, insomnia, dizziness, and hallucinations are common. For RLS, common side effects include nausea, headache, fatigue, and somnolence.
Nausea, dizziness, somnolence, insomnia, constipation, asthenia
What to notice: These may occur at any time during treatment, particularly at the start or after dose increases.
What to do: Report persistent or troublesome symptoms to the prescriber. Do not stop treatment without medical advice. (1)
Headache, fatigue
What to notice: Commonly reported in RLS patients.
What to do: Discuss with the prescriber if they are severe or persistent. (1)
New or worsening symptoms
What to notice: Any unexpected changes in behavior, mood, or physical condition, especially those listed in the serious warnings.
What to do: Contact the prescriber immediately for evaluation. (1)
Serious warnings
Falling asleep during activities of daily living — high
Symptoms: Sudden onset of sleep while engaged in routine activities such as driving, eating, or talking, sometimes without any prior drowsiness.
Action: Do not drive or operate dangerous machinery until you know how pramipexole affects you. Report any such episodes to the prescriber immediately. (1)
Symptomatic orthostatic hypotension — high
Symptoms: Dizziness, lightheadedness, fainting, especially when standing up from sitting or lying.
Action: Rise slowly. If symptoms are severe or cause falls, tell the prescriber. (1)
Impulse-control/compulsive behaviors — high
Symptoms: Intense urges to gamble, increased sexual thoughts or behaviors, compulsive shopping or eating, and other urges that you cannot control.
Action: Inform the prescriber if you or your family notice such changes. These behaviors are generally reversible when the prescriber reduces or discontinues pramipexole. (1)
Hallucinations — high
Symptoms: Seeing, hearing, or feeling things that are not real.
Action: Report to the prescriber, especially in older patients or those with advanced disease. (1)
Dyskinesia — moderate
Symptoms: Uncontrolled, involuntary movements, often exacerbated when also taking levodopa.
Action: Discuss with the prescriber; dose adjustments may be necessary. (1)
Withdrawal-emergent hyperpyrexia/confusion — high
Symptoms: Fever, muscle stiffness, altered consciousness, confusion resembling neuroleptic malignant syndrome, which can occur with rapid dose reduction or withdrawal.
Action: Do not stop pramipexole abruptly. The prescriber will taper the dose if discontinuation is indicated. (1)
RLS augmentation/rebound — moderate
Symptoms: Earlier onset of RLS symptoms in the evening, increase in symptom intensity, or spread to other limbs.
Action: Report to the prescribing clinician for evaluation. (1)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Dopamine antagonists (neuroleptics, metoclopramide) | May reduce the effectiveness of pramipexole. | Inform the prescriber if you are taking or start taking such medicines. (1) |
| Cimetidine | Increases pramipexole blood levels (AUC by 50%, half-life by 40%). | The prescriber may need to adjust the pramipexole dose. (1) |
| Other cationic-transport inhibitors (ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine) | May decrease oral clearance of pramipexole by approximately 20%. | Alert the prescriber if you take any of these, as dose adjustment may be needed. (1) |
Pregnancy, breastfeeding, kidney/liver function, age
Renal impairment
Dose adjustment is required in Parkinson's disease. For CrCl >60 mL/min: start 0.125 mg three times daily (max 1.5 mg three times daily). CrCl 35–59: start 0.125 mg twice daily (max 1.5 mg twice daily). CrCl 15–34: start 0.125 mg once daily (max 1.5 mg once daily). Not adequately studied in patients with CrCl <15 or on hemodialysis. For RLS, the titration interval is extended to 14 days in renal impairment. (1)
Pregnancy and breastfeeding
Use only if the potential benefit justifies the potential risk to the fetus. Animal studies have shown implantation inhibition and embryo resorption at high doses. Drug-related material is excreted in rat milk; it is not known if pramipexole is excreted in human milk. A decision to breastfeed or discontinue the drug should be made with the clinician. (1)
Children
Safety and effectiveness in children have not been established. No research note data available.
Monitoring
Before starting
- Confirm diagnosis and indication (idiopathic Parkinson's disease or moderate-to-severe primary RLS).
- Assess renal function (CrCl) for dose determination.
- Evaluate baseline blood pressure and risk of orthostatic hypotension.
- Discuss the potential for sleep attacks, impulse control disorders, and hallucinations with the patient and family.
During treatment
- Monitor for excessive drowsiness or sudden sleep episodes; advise against driving if they occur.
- Check for orthostatic symptoms and blood pressure changes, especially during dose escalation.
- Ask about new or worsening urges, compulsive behaviors, and hallucinations.
- Assess for dyskinesia in Parkinson's patients, particularly when combined with levodopa.
- Watch for signs of withdrawal syndrome if dose is reduced or stopped; taper gradually.
Storage
Store at 25°C (77°F); excursions permitted between 15–30°C (59–86°F). Protect from light. Keep out of reach of children.
Study the drug class: Antiparkinsonian agents
Professional information
Clinician-facing context only. Use the current local indication, dosing table, and product information. The research notes reflect a single US prescribing information source (circa 2009).
United States
Indication: Parkinson's disease (normal renal function)
Dose summary: Start 0.375 mg/day in three divided doses. Increase gradually by the prescriber every 5–7 days. Usual maintenance: 1.5–4.5 mg/day in three divided doses.
Renal context: For CrCl >60: start 0.125 mg TID (max 1.5 mg TID); CrCl 35–59: start 0.125 mg BID (max 1.5 mg BID); CrCl 15–34: start 0.125 mg once daily (max 1.5 mg daily). Not studied in CrCl <15 or hemodialysis. (1)
United States
Indication: Restless Legs Syndrome (RLS)
Dose summary: Start 0.125 mg once daily, taken 2–3 hours before bedtime. Increase by the prescriber every 4–7 days if needed. Typical range: 0.125–0.5 mg daily.
Renal context: In renal impairment, extend the titration interval to 14 days. (1)
Hepatic guidance
No hepatic impairment dosing guidance provided in the research notes.
Overdose note
No specific overdose management was detailed in the research notes. Standard supportive care and monitoring are advised. (1)
Frequently asked questions
Can pramipexole cause me to fall asleep during the day without warning?
Yes. Some patients have reported falling asleep suddenly during everyday activities like driving, even without feeling drowsy. You should not drive or do anything that requires alertness until you know how the medicine affects you, and report any such events to the prescriber immediately. (1)
Can I stop taking pramipexole abruptly?
No. Stopping suddenly can cause a serious withdrawal syndrome with fever, confusion, and muscle stiffness. The prescriber must taper the dose gradually if discontinuation is needed. (1)
What should I do if I develop strong urges to gamble, spend money, or engage in unusual sexual behavior?
These are known impulse-control side effects of pramipexole. You should tell the prescriber right away because these behaviors usually stop when the dose is reduced or the medicine is gradually discontinued. (1)
What is the mechanism of action of pramipexole?
Pramipexole is a non-ergot dopamine agonist. Its exact mechanism in Parkinson's disease and RLS is not fully established. (1)
What is the generic name of Pramipexole?
The generic name is pramipexole. It is sold under brand names including Mirapex. (1)
What class of drug is pramipexole?
Pramipexole is classed as: Dopamine agonist. (1)
References
- MIRAPEX (pramipexole dihydrochloride) tablets, Boehringer Ingelheim (repackaged by Physicians Total Care), label revision April 2009U.S. Food and Drug Administration (via DailyMed) · United States · dated April 2009 · accessed 2026-08-08 · source 1
- PRAMIPEXOLE DIHYDROCHLORIDE TABLET [BRYANT RANCH PREPACK] — US prescribing information (DailyMed SPL)U.S. National Library of Medicine (DailyMed) · US · accessed 2026-08-14 · source 2
- Pramipexole — patient drug information (MedlinePlus)U.S. National Library of Medicine (MedlinePlus) · US · accessed 2026-08-14 · source 3
- Pramipexole dihydrochloride — FDA approval record (Drugs@FDA ANDA203354)U.S. Food and Drug Administration · US · accessed 2026-08-14 · source 4
- pramipexole — RxNorm normalized drug concept (RXCUI 236747)U.S. National Library of Medicine (RxNorm) · US · accessed 2026-08-14 · source 5
Brand names by country
Single-ingredient pramipexole names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
Canada
- MIRAPEX